Company intelligence / Profile preview
ImmunoACT
Navi Mumbai, Maharashtra, Indiaimmunoact.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
ImmunoACT has developed NexCAR19, India's first home-grown CAR-T therapy at a fraction of global costs. The company has conducted clinical trials for pediatric B-ALL in India.
- Therapeutic areas
- Oncology
- Modalities
- Cell therapyGene therapyCAR-T cell therapy
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
IIT BombayTata Memorial Centre (TMC)
Beyond the preview
Go deeper on ImmunoACT.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ImmunoACT.